Retatrutide Peptide Cas No.2381089-83-2
Product source: chemically synthesized peptides
Product content: ≥ 98%
CAS NO：2381089-83-2
Detection method: HPLC
Active ingredient: Retatrutide
Product Description: White to off white solid
Product use: obesity research, type 2 diabetes mechanism exploration
Product packaging: Customized as needed: 1mg/10mg/20mg/50mg/100mg/500mg/1g, etc
Product storage: -20 ℃, dark, moisture-proof, sealed and dry
Shelf life: 24 months
Retatrutide API Peptide | Triple Agonist | CAS 2381089-83-2
Retatrutide (LY3437943) is a pioneering unimolecular triple receptor agonist, meticulously engineered for high-affinity activation of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. At Xi'an Tihealth, we provide pharmaceutical-grade Retatrutide (C221H342N62O68S) synthesized via advanced solid-phase peptide synthesis (SPPS). This triple-action mechanism facilitates unparalleled metabolic regulation, combining glucose-dependent insulinotropic effects with potent thermogenic energy expenditure and anorexigenic signaling for advanced obesity and T2DM research.
⚠️ REGULATORY COMPLIANCE & RESEARCH USE ONLY (RUO)
Research Specification: Retatrutide is supplied exclusively as a raw material API for professional laboratory research and clinical investigational studies. It is NOT a finished pharmaceutical product for consumer use.
Handling Requirement: Storage must be maintained at -20°C in a lyophilized state to prevent peptide bond hydrolysis. Xi'an Tihealth Biotechnology Co., Ltd. assumes no liability for unauthorized clinical application or off-label usage in non-compliant settings.
Molecular Pharmacology: Triple Agonism Metabolic Synergy
Retatrutide achieves metabolic homeostasis through a synergistic triad of hormonal pathways:
- GIP Receptor Potentiation: Enhances postprandial insulin secretion and stabilizes β-cell function, providing a potent foundation for glycemic control.
- GLP-1 Receptor Modulation: Activates hypothalamic satiety centers to induce anorexigenic effects while delaying gastric emptying to flatten postprandial glucose spikes.
- Glucagon (GCG) Receptor Activation: Distinctively drives hepatic fatty acid oxidation and brown adipose tissue thermogenesis, maximizing systemic energy expenditure beyond dual-agonist capabilities.
Retatrutide Technical Data Sheet (TDS) Profile
| Analytical Parameter | Pharmaceutical Specification |
|---|---|
| Chemical Name | Retatrutide; LY3437943 |
| CAS Number | 2381089-83-2 |
| Assay (HPLC, Anhydrous) | ≥ 98.0% - 99.0% |
| Molecular Formula | C221H342N62O68S |
| Identification | ESI-MS / HPLC Fingerprinting Verified |
| Counter Ion | Acetate (Customizable TFA-free options available) |
Bench Note: For maximum biological activity in R&D protocols, ensure the peptide is reconstituted in sterile, buffered saline immediately before use. Avoid multiple freeze-thaw cycles once the lyophilized crystalline mass is solubilized.
Global Procurement & R&D FAQ
Semaglutide is a selective GLP-1R agonist. Retatrutide is a triple agonist (GLP-1R, GIPR, GCGR). The addition of the Glucagon receptor pathway uniquely stimulates energy expenditure via thermogenesis, offering a more comprehensive profile for complex obesity research.
What measures are taken to ensure peptide batch consistency?At Xi'an Tihealth, each batch undergoes high-resolution HPLC to verify purity and ESI-MS to confirm molecular identity. We provide full COAs including residual moisture and solvent audits to ensure the API meets the stringent requirements of global pharmaceutical R&D labs.
Xi'an Tihealth Biotechnology Compliance Statement: Raw material API for industrial R&D only. User assumes all risks for unauthorized clinical usage. ISO 9001:2015 Certified.
Hot Tags: retatrutide peptide cas no.2381089-83-2, China retatrutide peptide cas no.2381089-83-2 manufacturers, suppliers, factory, tranexamic powder
You Might Also Like
Send Inquiry